山姆·奥特曼表示，OpenAI一旦上市将把使命置于股价之上，即使股价“大幅下跌”。OpenAI首席执行官在接受《名利场》采访时做出上述表态，该采访于10月5日发表。
Sam Altman said OpenAI will put its mission ahead of its share price once it goes public, even if the stock “falls a lot”. The OpenAI chief executive said it in an interview with Vanity Fair, published on 5 October.
《名利场》全球编辑总监马克·吉杜奇于9月11日在旧金山录制了这次对话。这是两次采访中的第一次。《名利场》在节目中披露，其母公司康德纳仕与OpenAI达成了内容合作协议。“那就让它跌吧”吉杜奇询问上市是否会改变公司的灵魂。奥特曼表示，OpenAI不会像其他上市公司那样。
Vanity Fair global editorial director Mark Guiducci recorded the conversation in San Francisco on 11 September. It was the first of two interviews. Vanity Fair said on air that its parent company, Condé Nast, has a content deal with OpenAI. “Then it falls”Guiducci asked whether going public would change the soul of the company. Altman said OpenAI will not be like other public companies.
“即使我们上市——我们并不急于这么做——我们仍将拥有一个管理我们的非营利实体，我们会提醒投资者以及任何考虑购买我们股份的人，我们将把使命放在首位。”他说，他相信使命与强劲回报是兼容的。如果两者产生张力，使命优先，他说。奥特曼已经排除了2026年上市的可能性。
“Even when we go public, which we are not in a rush to do, we will still have a nonprofit that governs us, and we will remind investors and anyone that thinks about buying our shares that we are going to put the mission first.”He said he believes the mission and strong returns are compatible. If they are ever in tension, the mission wins, he said. Altman has already ruled out a listing in 2026.
吉杜奇问，如果OpenAI因未达利润目标导致股价下跌会怎样。
Guiducci asked what happens if the stock price falls because OpenAI misses its profit targets.
“那就让它跌吧。也许会大跌，我不知道。”他说，股价可能会在季度间剧烈波动。他说，耐心的投资者长期来看会感到满意。奥特曼准备以比潜在速度更慢的速度增长营收，他说。无股权，与一份遗憾奥特曼确认他不持有OpenAI的直接股权。他通过早期对Y Combinator的投资拥有“极其微小、微小的一丁点敞口”。他说这个选择是个错误，因为大多数人不会那样看待世界。
“Then it falls. Maybe it falls a lot, I don’t know.”He said the shares would probably be very volatile from quarter to quarter. He said patient investors would be happy over time. OpenAI is ready to grow revenue more slowly than it could, he said. No equity, and a regret Altman confirmed he holds no direct equity in OpenAI. He has “this tiny, tiny sliver of exposure” through an old Y Combinator investment. He said the choice was a mistake, because most people do not think about the world that way.
“而且奇怪的是，不持有股权反而成了这件破坏信任的大事。”他说他过去非常受金钱驱动，仍然喜欢好东西。但他说他不再想要更多“东西”了。这就是为什么他希望自己当初就拿了股票，他说。
“And weirdly, this big trust-destroying thing to not have equity.”He said he used to be very motivated by money and still likes nice things. But he said there is no more “stuff” he wants. That is why he wishes he had just taken the stock, he said.
古杜奇询问奥特曼这么做是否是为了权力。奥特曼回应称“那样更接近事实”。他表示自己这么做是为了从事世界上最有趣且最具影响力的工作，也是为了留下自己的印记。
Guiducci asked whether he does it for power. Altman said that “would be closer to true”. He said he does it for the most interesting and most impactful job in the world, and to leave a mark.
古杜奇随后列举了今年从OpenAI离职的高管名单，其中包括负责伦理、安全系统及数据中心工作的负责人。OpenAI的首席运营官布拉德·莱特卡普以及负责营收事务的高管也均已离职。
The executives who left Guiducci listed the executives who left OpenAI this year. They include its heads of ethics, safety systems and data centres. Its chief operating officer, Brad Lightcap, and its revenue chief also left.
奥特曼指出，整个人工智能行业正以科技史上前所未有的速度发展。如今，原本需要五年时间才能实现的公司增长，现在仅需一年便可达成。
Altman said the whole AI industry is growing at a pace without precedent in tech. About five years of company growth now happen in one, he said.
“我认为，有些人在公司发展的某个阶段表现出色，但在下一阶段却不再适合担任相应职务，这很正常。只不过通常这种情况的发生速度不会这么快。”据古杜奇介绍，目前OpenAI基金会已成为全球资产规模最大的基金会，规模甚至超过了盖茨基金会。该基金会近期承诺向阿尔茨海默病研究投入1亿美元，并计划今年至少支出10亿美元。
“I think it is normal that there are people who are great at one stage of a company that are not the right fit for the next. But normally it happens a little more slowly than this.”The foundation Guiducci said the OpenAI Foundation is now the largest in the world by assets, ahead of the Gates Foundation. It recently pledged $100m to Alzheimer’s research. The foundation plans to spend at least $1bn this year.
奥特曼称，基金会主要致力于健康与科学领域的发展，以及协助社会为人工智能时代的到来做好准备。他表示自己无法确定阿尔茨海默病何时能被治愈，但预计“未来几年内某些疾病的治疗将会取得实质性进展”。
Altman said its two main areas are health and science, and helping society prepare for AI. He said he does not know when Alzheimer’s will be cured. But he said he expects “real progress in the next few years for some diseases”.